An official website of the United States government
Home
Name
Unituxin
Alternate Names
Ch14.18
MOAB Ch14.18
dinutuximab
monoclonal antibody Ch14.18
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
monoclonal antibody
NSC Number
None
Primary Site
Brain
Histology
Neuroblastoma
Remarks
March 2015: FDA approved dinutuximab in combination with GM-CSF, Interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
The FDA granted dinutuximab orphan drug status and also rare pediatric disease priority.
The FDA granted dinutuximab orphan drug status and also rare pediatric disease priority.
Coding
This drug should be coded
